CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 35 enrolled
Drug / intervention
LY2605541drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01751399
NCT01751399Phase 1Completed
CompareCT.gov

A Single Dose Pharmacokinetic Study of LY2605541 in Subjects With Hepatic Impairment

Eli Lilly and Company·interventional·Posted Dec 18, 2012·Updated Oct 19, 2018

In Brief

A Phase 1 clinical trial evaluating LY2605541 for Healthy Volunteers and 2 related conditions. Completed, enrolled 35 participants across 2 sites in 2 countries.

Detailed Summary

The primary purpose of this study is to help answer the following research questions: * To evaluate how much of the study drug (LY2605541) is in the blood of participants with varying degrees of liver impairment compared to those with normal liver function * To assess the safety of LY2605541 and any side effects that might be associated with it

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers, Hepatic Insufficiency, Diabetes Mellitus, Type 2
CountriesGermany, Hungary
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 18, 2012
Enrollment StartDec 1, 2012
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 13.5 years ago

Interventions

LY2605541drug